期刊文献+

非小细胞肺癌患者血清CA125水平与疾病进展时间的相关性 被引量:8

Correlation Between Serum CA125 and Time to Progression(TTP) in Patient with Non-small Cell Lung Caner
原文传递
导出
摘要 [目的]评价非小细胞肺癌(NSCLC)患者血清糖类抗原(CA125)水平与疾病进展时间(TTP)的关系。[方法]对中国中医科学院广安门医院2006年10月~2009年10月收治的154例非小细胞肺癌患者的血清CA125水平与疾病进展时间的相关性进行回顾性研究。[结果]血清CA125水平与临床分期相关,Ⅳ期患者血清CA125水平明显高于ⅢB期(P<0.05)。血清CA125水平≥123U/ml的患者半年内进展的风险比CA125水平<123U/ml的患者增加89%(OR=1.889,95%CI:1.254~2.845,P=0.002)。[结论]血清CA125水平与患者疾病进展时间有明显的相关性,可通过检测CA125水平判断患者预后。 Abstract: [PurposelTo analyze the correlation between serum CA125 and time to progression (TTP) in the patients with non-small cell lung cancer (NSCLC). [Methodsl Retrospective study on the correlation between serum CA125 and TFP was conducted in 154 NSCLC cases from Guang' anmen Hospital, China Academy of Chinese Medical Science. [Resultsl The level of serum CA125in patients with stage Ⅳ was significantly higher than that in those with stage Ⅲ B (P〈0.05). In term of tumour progress risk in 6 months, the patients with a high level of serum CA125 (3 123U/ ml) had 89% higher risk than patients with a low level of serum CA125 (〈123U/ml) (P=0.002). [Couclusionl There is obvious correlation between the serum level of CA125 and TFP in patients with NSCI,C. The serum level of CA125 is a helpful prognostic index, which is especially valuable to evaluate prognosis and to establish the clinical therapeutic prnject.
出处 《中国肿瘤》 CAS 2012年第2期150-152,共3页 China Cancer
基金 国家自然科学基金(81072802)
关键词 非小细胞肺癌 糖类抗原125 疾病进展时间 预后 non-small cell lung cancer CA125 time to progression prognosis
  • 相关文献

参考文献2

二级参考文献2

共引文献35

同被引文献98

  • 1王旭莹.肿瘤标志物的临床检测方法及其应用[J].中国实用医药,2007,2(7):105-106. 被引量:17
  • 2张昕,张湘茹.肺癌肿瘤标志物的临床价值[J].癌症进展,2005,3(2):159-162. 被引量:42
  • 3杨刚,何安南,曹进平.肺癌血清CEA、CA-125、CA19-9联合检测的诊断价值[J].皖南医学院学报,2007,26(3):181-182. 被引量:9
  • 4Shibuya K, Hiraok M. Radiation therapy for lung cancer[J]. Gan to Kagaku Ryoho,2007,34(4) :544-549.
  • 5Okada M, Sakamoto T, Nishio W, et al. Characteristics and prognosisof patients after resection of nonsmall cell lung carci- noma measuring 2 cm or less in greatest dimension[J]. Canc- er,2003,98(3) :535-541.
  • 6Zhang Y H, Li Y, Chen C, et al. Carcinoem bryoniic antrgen level is related to turn or invasion into the serosa of the stoma- ehe study on 166 eases and suggestion for new therapy[J]. Hepatogastroenterology, 2009,56 ( 96) : 1750-1754.
  • 7潘铁成.实用肺癌外科临床手册[M]{H}北京:人民卫生出版社,20092.
  • 8Hatzidaki D,Agelaki S,Mavroudis D. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer[J].Clin Lung Cancer,2006,(01):49-55.
  • 9Yoshida K,Sugiura T,Takifuji N. Randomized phase Ⅱ trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer:JCOG 9515[J].{H}Lung Cancer,2007,(03):362-368.
  • 10Cusumano G,Margarifora S,Porziella V. Malignant Pleural Effusion[J].{H}Annali Italiani Di Chirurgia,2007,(05):389-391.

引证文献8

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部